Clinical Trials Directory
We are doing this study to find the most effective, safe dose of an experimental drug called ficerafusp alfa (BCA101 - the study drug) when it is given in combination with pembrolizumab for people who have metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
We are doing this study to collect data, liquid biopsies (blood and urine), and cancer specimens from women with primary epithelial ovarian, peritoneal, or tubal cancer. We are using this information and these samples to create a biobank that might identify future therapeutic targets and help develop new therapies for these types of cancer.
We are doing this study to find the most effective, safe dose of an experimental drug called BHV-1530 (the study drug) for adults who have advanced or metastatic solid tumors.
We are doing this study to find the most effective, safe dose of an experimental drug called BNT326. We want to know how well it works when it is given on its own and in combination with an immunotherapy drug.
This study includes several groups of patients with different types of cancer. Each group tests a new medicine called AI 081 at different dose levels. In some groups, people are placed into two groups by chance to receive different doses to find the best amount of the medicine. In other groups, the medicine is given along with standard chemotherapy. There is also a group where everyone receives the same dose of the medicine. The goal is to learn which dose is safest and works best for different types of cancer.
The study begins with a screening period that lasts about four weeks. During this time, doctors check your health with a medical history, an exam, blood and urine tests, heart tests, and imaging scans. If you qualify, you will start the treatment part of the study to see how well the chosen dose works. The study drug is called BH 30643. It is a pill taken by mouth on an empty stomach, usually once or twice a day. During the first three weeks, there are several clinic visits. After that, visits happen about every three weeks until Cycle 9, and then about every six weeks. You will also have regular blood tests, heart tests, and scans every six weeks, then every twelve weeks after thirty six weeks.
The study starts with a screening period that lasts about 4 weeks and includes 1 or 2 visits. Treatment can last up to about 2 years with up to 43 visits. After treatment ends, follow-up continues for about 1 year with up to 6 visits. The study medicine is given through an IV every 3 weeks, and each visit lasts about 60 minutes. In Part 1 of the study, researchers test the medicine BMS 986525 by itself or with another medicine called nivolumab to find a safe dose. In Part 2, the chosen dose or doses are tested in larger groups. If more than one dose is available, a computer may randomly choose which dose a person receives.
We are doing this study to find out if patients with SAA who have not received previous treatment for this diagnosis can be treated safely and effectively with transplant as their first therapy.